The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with the inclusion of HAPB3.
Effective from the 6th October 2020, the ToxNav® panel will contain one additional genetic variant (HAPB3; rs56038477). This variant has been shown to be associated with severe DPYD toxicity. This will bring the panel from 19 variants to a total of 20 variants.
This change reflects our updated internal clinical validation and recent updates to the CPIC Guidelines for Fluoropyrimidines and DPYD.
The clinical impact of the inclusion of HAPB3 is an expected increase in the frequency of patients requiring dose modulation or for whom fluoropyrimidine (including 5-FU or capecitabine) based therapy is contraindicated by 0.5-1% above the existing rate. No other aspect of the ToxNav® assay will be impacted by this change.
It is incredibly exciting to be on the forefront of genomics and its roll out into the clinic. The team at OCB have previously demonstrated that our ToxNav® algorithm provided clinically meaningful information that altered the way clinicians prescribed fluoropyrimidine based chemotherapy for patients with colorectal cancer. The inclusion of HAPB3 in the ToxNav® panel casts the ‘genetic net’ even wider to ensure that OCB can make cancer treatment pathways as safe as possible.
If you would like to know more about this change or anything else related to ToxNav®, please reach out to one of the team.
Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ®
OXFORD, UK – April 21st, 2021 – OncoProg ® is a cutting-edge digital pathology prognosis tool that provides a more complete understanding of how aggressive a patient’s colorectal cancer is likely to be. OncoProg ® consists of proprietary software which combines a unique algorithm in which colorectal cancer specimens are assessed from patients who have undergone removal of their primary tumours. Tumour ploidy and stromal components are identified and, using a patented system, a risk of recurrence score calculated. This system links the prognostic algorithm to a method for measuring all the contributory elements in a single colorectal cancer formalin fixed paraffin embedded (FFPE) sample.
The change from ColoProg ® to OncoProg ® has arisen due to early data now demonstrating that the technology shows promise in more than one cancer type. Oxford Cancer Biomarkers is a pioneer in precision medicine techniques. Following the successful launch of our pharmacogenomic ToxNav ® DPYD test, the company is working hard to deploy the first iteration of OncoProg ® to drastically enhance the decision-making capabilities of Oncologists and improve patients’ lives.
If you would like to know more about this technology, please get in touch with one of the team.
About OncoProg ®
OncoProg ® determines the prognosis of Stage II colorectal cancer patients after treatment with fluoropyrimidine-based chemotherapy. The platform utilises digital pathology to examine specimens in order to determine DNA ploidy and tumour stroma content.
Biomarkers are combined to stratify patients into categories informing on risk of recurrence:
- High risk (non-diploid and high stroma)
- Intermediate risk (non-diploid and low stroma OR diploid and high stroma)
- Low risk (diploid and low stroma)
OncoProg ® provides clinicians and patients with information that, together with other relevant clinical parameters such as co-morbidities and performance status, can help assist in the choice of chemotherapy treatment regimens after initial surgery. OncoProg® is driven by artificial intelligence, will eventually be compatible for use with other types of cancer .
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers started as a spin off from the University of Oxford. The aim of the company was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer.
Since then, the company has built a world class development team consisting of industry professionals, leading scientists and oncologists whilst maintaining strong links to the University of Oxford. Together, we have launched our first product – ToxNav ® – and are positioned to launch OncoProg ® into the UK this year (2021). Our vision is to be the leading pioneer in biomarker technology and deploy artificial intelligence that places individual patients at the heart of cancer care.
Contact
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743